CaDAnCe-101 (NCT05006716) is a Phase 1/2, open-label, dose-escalation and expansion trial evaluating BGB-16673, a Bruton tyrosine kinase (BTK) degrader, in patients with relapsed/refractory B-cell malignancies, including chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), follicular lymphoma (FL), and marginal zone lymphoma (MZL).
CaDAnCe-101 (NCT05006716) is a Phase 1/2, open-label, dose-escalation and expansion trial evaluating BGB-16673, a Bruton tyrosine kinase (BTK) degrader, in patients with relapsed/refractory B-cell malignancies, including chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), follicular lymphoma (FL), and marginal zone lymphoma (MZL).
Reading
BGB-11417-102 (NCT04883957) is a Phase 1 trial of sonrotoclax in adult patients with mature B-cell malignancies.
Reading
BGB-11417-101 (NCT04277637) is a Phase 1a/1b, open-label, dose-escalation and expansion trial of sonrotoclax in patients with mature B-cell malignancies.
Reading
BGB-3111-215 (NCT04116437) is a Phase 2, multicenter, single-arm trial of zanubrutinib in patients with previously treated B-cell lymphoma intolerant of prior treatment with ibrutinib and/or acalabrutinib.
Reading
